LifeMD, Inc. (LFMD)

LifeMD, Inc. stock has experienced significant negative impacts in the past six months, losing approximately 45% since October 31, 2025. As of February 5, 2026, the share price was $2.77, representing a decline of 55.61% from $6.24 on February 6, 2025. Key events contributing to this decline include a disappointing Q3 2025 earnings report and revenue adjustments, a downward revision of full-year 2025 revenue guidance, and a securities class action lawsuit alleging misleading financial information.

Information explicitly detailing the demand seasonality for LifeMD, Inc.'s products and services is not readily available in the provided search results. Therefore, no clear demand seasonality can be determined from the available information.

LifeMD, Inc. operates as a direct-to-patient telehealth company, connecting consumers with healthcare professionals across various indications in the United States. The company primarily functions within the Healthcare Technology, Virtual Care, and Primary Care sectors, and the Health Information Services and Medical - Pharmaceuticals industries. LifeMD's major products and services are offered through several telehealth platform brands including ShapiroMD, RexMD, LifeMD Primary Care, Cleared, Nava MD, GLP-1 for Weight Management, and WorkSimpli Segment. LifeMD fully divested its majority stake in WorkSimpli subsequent to Q3 2025, positioning itself as a pure-play telehealth and pharmacy platform.

LifeMD, Inc. primarily operates in the United States. The company has a 50-state affiliated provider network and has expanded its Medicare fee-for-service initiative to cover over 21 million Medicare Part B beneficiaries across 26 states, with plans to reach 49 states and over 60 million beneficiaries by the end of Q2 2025.

LifeMD's brand reputation in the past year has been significantly impacted by negative events, most prominently the federal securities fraud class action lawsuit filed in October 2025. The lawsuit alleges that the company provided misleading financial information and growth prospects to investors, leading to a substantial drop in stock price. The disappointing Q3 2025 earnings report, prior period revenue adjustments, and the downward revision of full-year guidance further contributed to a negative perception of the company's financial management and operational performance.

LifeMD, Inc. has a significant institutional ownership presence, with 220 institutional owners holding a total of 24,769,066 shares, representing 57.14% of the company's shares as of August 19, 2025. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Renaissance Technologies Llc. Among individual owners, CEO Justin Schreiber held 2,703,715 shares as of June 2025, representing 5.7% of the company.